$IPA ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
https://www.businesswire.com/news/home/202203...-Year-2022
VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for third quarter fiscal year 2022, which ended January 31, 2022.
Third Quarter Fiscal Year 2022 Financial Summary*
(All comparisons are to the period ended January 31, 2022)
The Company achieved Project revenue of $4.1 million, an increase of $0.7 million or 22.6% as compared to Project revenue of $3.3 million from the same year ago period.
The Company’s total revenue of $4.8 million was an increase of $0.3 million or 6.6% as compared to total revenue of $4.5 million from the same year ago period.
The Company, primarily through its subsidiary Talem Therapeutics LLC, invested $1.8 million in strategic research and development costs as compared to an investment of nil in the same year ago-period.
The Company recorded a net loss of $3.8 million, as compared to net loss of $1.3 million as compared to the same year-ago period.
As of January 31, 2022, the Company held cash of $33.0 million.
*Expressed in Canadian dollars, unless otherwise indicated.
Dr. Jennifer Bath, CEO of ImmunoPrecise, stated, “We are pleased with both the progress and continued execution of IPA’s strategic operating plan this quarter. In filling key roles within the organization’s sales and marketing teams, we believe we have provided the critical infrastructure to ramp growth of the commercial business. Consequently, project revenues in the CRO business increased a healthy 22.6% in the period, and we remain optimistic in our ability to grow revenues organically through existing clients and through new business wins alike. Additionally, we are moving the development of Polytope® (TATX-03), Talem’s lead pipeline asset, forward on multiple fronts both in-house and through external partnering.”
“TATX-03, currently in pre-IND phase — is tracking well against development timelines. As such, we expect to submit an investigational new drug application (IND) with the FDA by the third quarter of the calendar year. A highlight of this development program has been the absence of any significant regulatory hurdles to date, as we believe IPA’s conservative development and working in lockstep with the FDA inquiry process has paid off. This is against the backdrop of a rapidly evolving regulatory framework required to address the shifting future landscape around the fight against COVID-19. In tandem to the Company’s independent development efforts, we have also recently announced a partnering agreement with Elektrofi, to participate in a U.S. Defense Health Agency (DHA) funded program that will leverage funds from Elektrofi’s contract with the DHA Small Business Innovation Research program with the U.S. Department of Defense (DoD),” concluded Dr. Bath.
Recent Third Quarter Fiscal 2022 Operational Highlights
IPA was selected to work with Elektrofi on COVID-19 therapeutic delivery and future pandemic preparation under SBIR contract from Defense Health Agency (DHA) within the US Department of Defense
Polytope® TATX-03 aggregate program update:
No pharmacokinetic aberrations in in vivo animal model study.
Injection with TATX-03 is well tolerated - with a significant safety margin and no clinical signs of toxicity.
Maximum tolerated dose study evaluating up to a 12.5-fold higher amount than the highest dose anticipated for use in humans did not uncover any observable clinical signs of toxicity.
SARS-CoV-2 PolyTope® antibody cocktail retains in vitro binding efficacy against viral variants-of-concern tested to date.
Initiated assessment of retention of binding to cell-associated Omicron spike protein variant (B.1.1.529).
Improved protein homogeneity in PolyTope® antibody cocktail for production purposes.
Demonstrated in vitro pseudovirus assays, PolyTope® advanced immunotherapeutic TATX-03 prevents infection of cells by SARS-CoV-2 variant-of-concern, Omicron, and all variants of concern tested to date.
Established manufacturing collaboration with ChemPartner Biologics for PolyTope® TATX-03 Antibody Cocktail.
Talem Therapeutic filed a non-provisional U.S. patent application and concurrent international PCT (Patent Cooperation Treaty) and other national patent applications relating to the discovery of PolyTope® TATX-03, its in vitro and in vivo effects, and therapeutic use.
Leased future new space for laboratory expansion at IPA Europe in a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.
Financial Results
Revenue
Project revenue of $4.1 million was $0.7 million, or 22.6%, higher than the same period last year. Growth is driven primarily by the Company’s B cell Select® platform, with expansion in both the number and size of projects under contract leading to revenue increases.
The Company achieved revenue of $4.8 million during the three months ended January 31, 2022, a 6.6% increase from the three months ended January 31, 2021.
Product sales during the three months ended January 31, 2022, totaled $0.5 million, a decrease of $0.7 million, or 60.9%, compared to the same period last year. The higher product sales during the three months ended January 31, 2021, relates to the Company’s sale of its first internally generated therapeutic antibody asset. The Company achieved an increase in catalog sales of $0.4 million during the three months ended January 31, 2022, as compared to the same period last year. Catalog products include antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors and hybridoma licensing for research purposes.
Research & Development
Research and development increased to $1.8 million from nil in 2021, due to the strategic investment in research the Company is undertaking, including the Company’s SARS-CoV-2 PolyTope® cocktail and other research projects.
Net Loss
The Company recorded a net loss of $3.8 million during the three months ended January 31, 2022, compared to a net loss of $1.3 million for the three months ended January 31, 2021. The $2.5 million increased net loss is primarily due to the Company’s investment in R&D and salaries and benefits to support the Company’s strategic plans and operations.
https://www.businesswire.com/news/home/202203...-Year-2022
VICTORIA, British Columbia--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for third quarter fiscal year 2022, which ended January 31, 2022.
Third Quarter Fiscal Year 2022 Financial Summary*
(All comparisons are to the period ended January 31, 2022)
The Company achieved Project revenue of $4.1 million, an increase of $0.7 million or 22.6% as compared to Project revenue of $3.3 million from the same year ago period.
The Company’s total revenue of $4.8 million was an increase of $0.3 million or 6.6% as compared to total revenue of $4.5 million from the same year ago period.
The Company, primarily through its subsidiary Talem Therapeutics LLC, invested $1.8 million in strategic research and development costs as compared to an investment of nil in the same year ago-period.
The Company recorded a net loss of $3.8 million, as compared to net loss of $1.3 million as compared to the same year-ago period.
As of January 31, 2022, the Company held cash of $33.0 million.
*Expressed in Canadian dollars, unless otherwise indicated.
Dr. Jennifer Bath, CEO of ImmunoPrecise, stated, “We are pleased with both the progress and continued execution of IPA’s strategic operating plan this quarter. In filling key roles within the organization’s sales and marketing teams, we believe we have provided the critical infrastructure to ramp growth of the commercial business. Consequently, project revenues in the CRO business increased a healthy 22.6% in the period, and we remain optimistic in our ability to grow revenues organically through existing clients and through new business wins alike. Additionally, we are moving the development of Polytope® (TATX-03), Talem’s lead pipeline asset, forward on multiple fronts both in-house and through external partnering.”
“TATX-03, currently in pre-IND phase — is tracking well against development timelines. As such, we expect to submit an investigational new drug application (IND) with the FDA by the third quarter of the calendar year. A highlight of this development program has been the absence of any significant regulatory hurdles to date, as we believe IPA’s conservative development and working in lockstep with the FDA inquiry process has paid off. This is against the backdrop of a rapidly evolving regulatory framework required to address the shifting future landscape around the fight against COVID-19. In tandem to the Company’s independent development efforts, we have also recently announced a partnering agreement with Elektrofi, to participate in a U.S. Defense Health Agency (DHA) funded program that will leverage funds from Elektrofi’s contract with the DHA Small Business Innovation Research program with the U.S. Department of Defense (DoD),” concluded Dr. Bath.
Recent Third Quarter Fiscal 2022 Operational Highlights
IPA was selected to work with Elektrofi on COVID-19 therapeutic delivery and future pandemic preparation under SBIR contract from Defense Health Agency (DHA) within the US Department of Defense
Polytope® TATX-03 aggregate program update:
No pharmacokinetic aberrations in in vivo animal model study.
Injection with TATX-03 is well tolerated - with a significant safety margin and no clinical signs of toxicity.
Maximum tolerated dose study evaluating up to a 12.5-fold higher amount than the highest dose anticipated for use in humans did not uncover any observable clinical signs of toxicity.
SARS-CoV-2 PolyTope® antibody cocktail retains in vitro binding efficacy against viral variants-of-concern tested to date.
Initiated assessment of retention of binding to cell-associated Omicron spike protein variant (B.1.1.529).
Improved protein homogeneity in PolyTope® antibody cocktail for production purposes.
Demonstrated in vitro pseudovirus assays, PolyTope® advanced immunotherapeutic TATX-03 prevents infection of cells by SARS-CoV-2 variant-of-concern, Omicron, and all variants of concern tested to date.
Established manufacturing collaboration with ChemPartner Biologics for PolyTope® TATX-03 Antibody Cocktail.
Talem Therapeutic filed a non-provisional U.S. patent application and concurrent international PCT (Patent Cooperation Treaty) and other national patent applications relating to the discovery of PolyTope® TATX-03, its in vitro and in vivo effects, and therapeutic use.
Leased future new space for laboratory expansion at IPA Europe in a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.
Financial Results
Revenue
Project revenue of $4.1 million was $0.7 million, or 22.6%, higher than the same period last year. Growth is driven primarily by the Company’s B cell Select® platform, with expansion in both the number and size of projects under contract leading to revenue increases.
The Company achieved revenue of $4.8 million during the three months ended January 31, 2022, a 6.6% increase from the three months ended January 31, 2021.
Product sales during the three months ended January 31, 2022, totaled $0.5 million, a decrease of $0.7 million, or 60.9%, compared to the same period last year. The higher product sales during the three months ended January 31, 2021, relates to the Company’s sale of its first internally generated therapeutic antibody asset. The Company achieved an increase in catalog sales of $0.4 million during the three months ended January 31, 2022, as compared to the same period last year. Catalog products include antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors and hybridoma licensing for research purposes.
Research & Development
Research and development increased to $1.8 million from nil in 2021, due to the strategic investment in research the Company is undertaking, including the Company’s SARS-CoV-2 PolyTope® cocktail and other research projects.
Net Loss
The Company recorded a net loss of $3.8 million during the three months ended January 31, 2022, compared to a net loss of $1.3 million for the three months ended January 31, 2021. The $2.5 million increased net loss is primarily due to the Company’s investment in R&D and salaries and benefits to support the Company’s strategic plans and operations.
